AKT1 and metabolic dysfunction-associated steatotic liver disease: MIYAIRI 588, a butyrate-producing probiotic from Japan, prevented hepatic steatosis from developing into liver cancer in a rat NAFLD model through activating of hepatic adenosine 5′-monophosphate-activated protein kinase (AMPK), AKT, nuclear factor erythoid 2-related factor 2 (Nrf2) and its targeted antioxidative enzymes (71).